| Human immunodeficiency virus I infection
Delstrigo vs Juluca
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Delstrigo vs Juluca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJuluca has a higher rate of injection site reactions vs Delstrigo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Juluca but not Delstrigo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Delstrigo
Juluca
At A Glance
Oral
Once daily
NNRTI/NRTI combination
Oral
Once daily
INSTI/NNRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet orally once daily with or without food in adults and pediatric patients weighing at least 35 kg.
With rifabutin co-administration Take one tablet of DELSTRIGO once daily plus one tablet of doravirine 100 mg (PIFELTRO) approximately 12 hours after the DELSTRIGO dose for the duration of rifabutin co-administration.
Human immunodeficiency virus I infection One tablet (dolutegravir 50 mg/rilpivirine 25 mg) orally once daily with a meal; if coadministered with rifabutin, take an additional rilpivirine 25-mg tablet with JULUCA once daily with a meal for the duration of rifabutin coadministration.
Contraindications
- Co-administration with strong CYP3A inducers, including carbamazepine, oxcarbazepine, phenobarbital, phenytoin, enzalutamide, rifampin, rifapentine, mitotane, or St. John's wort
- Previous hypersensitivity reaction to lamivudine
- Previous hypersensitivity reaction to dolutegravir or rilpivirine
- Coadministration with dofetilide
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with systemic dexamethasone (more than a single-dose treatment)
- Coadministration with St John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
Adverse Reactions
Most common (>=5%) Dizziness, nausea, abnormal dreams
Serious Severe acute exacerbation of hepatitis B, new onset or worsening renal impairment, bone loss and mineralization defects, immune reconstitution syndrome
Postmarketing Stevens-Johnson syndrome/toxic epidermal necrolysis, hepatitis, lactic acidosis, hepatic steatosis, rhabdomyolysis, acute renal failure, Fanconi syndrome, anaphylaxis, anemia
Most common (>=2%) Diarrhea, headache, nausea
Serious Depressive disorders including suicidal ideation, hepatotoxicity, skin and hypersensitivity reactions
Postmarketing Acute liver failure, hepatotoxicity, weight increase, arthralgia, myalgia, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Pharmacology
DELSTRIGO combines doravirine, an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase; lamivudine, a nucleoside analogue NRTI that terminates HIV-1 DNA chain elongation after phosphorylation to lamivudine triphosphate; and tenofovir disoproxil fumarate, a nucleotide analogue prodrug that, following conversion to tenofovir diphosphate, competitively inhibits HIV-1 reverse transcriptase and causes DNA chain termination.
JULUCA is a fixed-dose combination of dolutegravir, an integrase strand transfer inhibitor (INSTI) that blocks the strand transfer step of retroviral DNA integration essential for HIV replication, and rilpivirine, a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) that non-competitively inhibits HIV-1 reverse transcriptase without inhibiting human cellular DNA polymerases alpha, beta, or gamma.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Delstrigo
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Juluca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (1/12) · Qty limit (11/12)
UnitedHealthcare
Delstrigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Juluca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Delstrigo
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Juluca
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Delstrigo or Pifeltro Savings CouponCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DelstrigoView full Delstrigo profile
JulucaView full Juluca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.